195 related articles for article (PubMed ID: 12622764)
1. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection.
Wong WM; Gu Q; Lam SK; Fung FM; Lai KC; Hu WH; Yee YK; Chan CK; Xia HH; Yuen MF; Wong BC
Aliment Pharmacol Ther; 2003 Feb; 17(4):553-60. PubMed ID: 12622764
[TBL] [Abstract][Full Text] [Related]
2. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication.
Zullo A; Hassan C; De Francesco V; Lorenzetti R; Marignani M; Angeletti S; Ierardi E; Morini S
Dig Liver Dis; 2003 Apr; 35(4):232-6. PubMed ID: 12801033
[TBL] [Abstract][Full Text] [Related]
3. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.
Nista EC; Candelli M; Cremonini F; Cazzato IA; Di Caro S; Gabrielli M; Santarelli L; Zocco MA; Ojetti V; Carloni E; Cammarota G; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2003 Sep; 18(6):627-33. PubMed ID: 12969089
[TBL] [Abstract][Full Text] [Related]
4. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Perri F; Festa V; Merla A; Barberani F; Pilotto A; Andriulli A
Aliment Pharmacol Ther; 2003 Oct; 18(8):815-20. PubMed ID: 14535875
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
[TBL] [Abstract][Full Text] [Related]
6. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole.
Giannini EG; Bilardi C; Dulbecco P; Mamone M; Santi ML; Testa R; Mansi C; Savarino V
J Clin Gastroenterol; 2006 Jul; 40(6):515-20. PubMed ID: 16825934
[TBL] [Abstract][Full Text] [Related]
7. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Gambaro C; Bilardi C; Dulbecco P; Iiritano E; Zentilin P; Mansia C; Usai P; Vigneri S; Savarino V
Dig Liver Dis; 2003 Nov; 35(11):763-7. PubMed ID: 14674665
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication].
Jung HS; Shim KN; Baik SJ; Na YJ; Kang MJ; Jung JM; Ha CY; Jung SA; Yoo K
Korean J Gastroenterol; 2008 May; 51(5):285-90. PubMed ID: 18516012
[TBL] [Abstract][Full Text] [Related]
9. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication.
Giannini EG; Bilardi C; Dulbecco P; Mamone M; Santi ML; Testa R; Mansi C; Savarino V
Aliment Pharmacol Ther; 2006 Jan; 23(2):281-7. PubMed ID: 16393308
[TBL] [Abstract][Full Text] [Related]
10. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levofloxacin, for Helicobacter pylori eradication.
Cammarota G; Cianci R; Cannizzaro O; Martino A; Fedeli P; Lecca PG; di Caro S; Cesaro P; Branca G; Gasbarrini G
J Clin Gastroenterol; 2004 Feb; 38(2):110-4. PubMed ID: 14745283
[TBL] [Abstract][Full Text] [Related]
11. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Nagahara A; Miwa H; Yamada T; Kurosawa A; Ohkura R; Sato N
Aliment Pharmacol Ther; 2001 Mar; 15(3):417-21. PubMed ID: 11207518
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
Borody TJ; Pang G; Wettstein AR; Clancy R; Herdman K; Surace R; Llorente R; Ng C
Aliment Pharmacol Ther; 2006 Feb; 23(4):481-8. PubMed ID: 16441468
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Perri F; Festa V; Clemente R; Villani MR; Quitadamo M; Caruso N; Bergoli ML; Andriulli A
Am J Gastroenterol; 2001 Jan; 96(1):58-62. PubMed ID: 11197288
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Cammarota G; Cianci R; Cannizzaro O; Cuoco L; Pirozzi G; Gasbarrini A; Armuzzi A; Zocco MA; Santarelli L; Arancio F; Gasbarrini G
Aliment Pharmacol Ther; 2000 Oct; 14(10):1339-43. PubMed ID: 11012480
[TBL] [Abstract][Full Text] [Related]
16. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
17. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Aktaş B; Başyiğit S; Yüksel O; Akkan T; Atbaşı ST; Uzman M; Yılmaz B; Şimşek G; Nazlıgül Y
Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):769-75. PubMed ID: 25919773
[TBL] [Abstract][Full Text] [Related]
18. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Isomoto H; Inoue K; Furusu H; Enjoji A; Fujimoto C; Yamakawa M; Hirakata Y; Omagari K; Mizuta Y; Murase K; Shimada S; Murata I; Kohno S
Aliment Pharmacol Ther; 2003 Jul; 18(1):101-7. PubMed ID: 12848631
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
[TBL] [Abstract][Full Text] [Related]
20. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
Hsu PI; Wu DC; Chen A; Peng NJ; Tseng HH; Tsay FW; Lo GH; Lu CY; Yu FJ; Lai KH
Eur J Clin Invest; 2008 Jun; 38(6):404-9. PubMed ID: 18435764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
